Cytokinetics, Incorporated announced the first commercial European launch of Myqorzo (aficamten) in Germany for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy… read more.
Substantial variations in referrals for advanced heart failure therapies are apparent across the UK and Ireland, with no obvious link to geographical location or social deprivation to explain… read more.
The MHRA confirmed that it granted a UK marketing authorisation to Wayrilz (rilzabrutinib) for adults with immune thrombocytopenia (ITP) whose previous treatments have not worked sufficiently. The approval… read more.
Clocking up 90 to 120 weekly minutes of strength (resistance) training may be the sweet spot for lowering the risk of death, suggests a 30 year study, published… read more.
BD (Becton, Dickinson and Company) announced the introduction of the Elyra Thulium Fiber Laser (TFL) System, an advanced laser platform developed to complete BD’s kidney stone care portfolio… read more.
The Lancet Oncology Commission warns the shortfall, driven by rising cancer rates and workforce gaps, will place significant strain on health systems worldwide, with the largest shortages expected in nursing and… read more.
Amid growing concern about the widespread off‑label use of sedative medications for sleep problems, Flinders University researchers have led a world‑first clinical trial examining how a commonly prescribed… read more.
On 21 May 2026, the CHMP adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Wegovy. The marketing authorisation… read more.
A new study highlights a critical gap: most clinical research studies that use imaging techniques such as amyloid positron emission tomography (PET) scans do not account for the… read more.
Researchers at UBC found that B.C.’s decision to provide universal, no-cost prescription contraception sharply reduced what patients pay, with the largest financial gains for people in their 20s…. read more.
Ironwood Pharmaceuticals announced that the FDA has approved the use of Linzess (linaclotide) in pediatric patients 2 years of age and older with functional constipation (FC). Linzess was… read more.
The total cost of emergency admissions for mental health among children and young people in England rose from £22.5 million in 2012/13 to £87.3 million in 2021/22, finds… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
